<DOC>
	<DOCNO>NCT00346073</DOCNO>
	<brief_summary>GSK Biologicals ' dTpa vaccine recently approve US Food Drug Administration ( FDA ) booster vaccination adolescent age 10 18 year . The ACIP recently issue provisional recommendation universal adult Tdap vaccination . The current study provide pivotal data support extend age range Boostrix vaccine include adult 19-64 year age .</brief_summary>
	<brief_title>Safety Immunogenicity GSK 's Tdap Vaccine ( Boostrix ) Adults Aged 19 64 Years</brief_title>
	<detailed_description />
	<mesh_term>Whooping Cough</mesh_term>
	<mesh_term>Tetanus</mesh_term>
	<mesh_term>Diphtheria</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>A healthy male female , 19 64 year age ( reach 65th birthday ) time study vaccination . Use investigational nonregistered product ( drug vaccine ) study vaccine ( ) within 30 day precede administration study vaccine , plan use active phase study . Chronic administration immunosuppressant within six month prior administration study vaccine . Planned administration/ administration vaccine foreseen study protocol within 30 day administration study vaccine ( exception influenza vaccine ) . Administration diphtheriatetanus ( Td ) booster within previous five year . Administration Tdap vaccine time prior study entry . History serious allergic reaction ( e.g . anaphylaxis ) follow tetanus toxoid , diphtheria toxoid pertussiscontaining vaccine component study vaccine .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Prophylaxis diphtheria , tetanus , pertussis</keyword>
	<keyword>Immunogenicity , booster , dTpa</keyword>
</DOC>